Degrading JAK2 in ALL by ruxolitinib-based PROTACs

Ижил төстэй зүйлс

• JAK inhibitors and myelofibrosis, Einstein and ruxolitinib
  -н: Claire Harrison
  Хэвлэсэн: (2015-04-01)
• Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements
  -н: Andrew Chase, зэрэг
  Хэвлэсэн: (2013-03-01)
• DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
  -н: Fenglei Li, зэрэг
  Хэвлэсэн: (2022-11-01)
• Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
  -н: M. V. Barabanshchikova, зэрэг
  Хэвлэсэн: (2016-03-01)
• Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
  -н: Sinan Ma, зэрэг
  Хэвлэсэн: (2022-07-01)